Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks.
Mallm JP, Iskar M, Ishaque N, Klett LC, Kugler SJ, Muino JM, Teif VB, Poos AM, Großmann S, Erdel F, Tavernari D, Koser SD, Schumacher S, Brors B, König R, Remondini D, Vingron M, Stilgenbauer S, Lichter P, Zapatka M, Mertens D, Rippe K. Mallm JP, et al. Among authors: poos am. Mol Syst Biol. 2019 May 22;15(5):e8339. doi: 10.15252/msb.20188339. Mol Syst Biol. 2019. PMID: 31118277 Free PMC article.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm KM, Müller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel K, Raab MS. Giesen N, et al. Among authors: poos am. Blood. 2023 Apr 6;141(14):1685-1690. doi: 10.1182/blood.2022017789. Blood. 2023. PMID: 36608320 Free article. Clinical Trial.
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.
Darawshi O, Muz B, Naamat SG, Praveen B, Mahameed M, Goldberg K, Dipta P, Shmuel M, Forno F, Boukeileh S, Pahima H, Hermann J, Raab MS, Poos AM, Weinhold N, Rosenbluh C, Gatt ME, Palm W, Azab AK, Tirosh B. Darawshi O, et al. Among authors: poos am. Cell Death Dis. 2022 Nov 18;13(11):969. doi: 10.1038/s41419-022-05421-4. Cell Death Dis. 2022. PMID: 36400754 Free PMC article.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau IW, Hänel M, Salwender HJ, Benner A, Raab MS, Goldschmidt H, Weinhold N. Mai EK, et al. Among authors: poos am. Blood Cancer J. 2023 Jan 4;13(1):1. doi: 10.1038/s41408-022-00772-9. Blood Cancer J. 2023. PMID: 36599831 Free PMC article. Clinical Trial.
Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C. Minner S, et al. Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14. Prostate. 2019. PMID: 30430607
Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.
Höflmayer D, Steinhoff A, Hube-Magg C, Kluth M, Simon R, Burandt E, Tsourlakis MC, Minner S, Sauter G, Büscheck F, Wilczak W, Steurer S, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Jacobsen F, Hinsch A, Poos AM, Oswald M, Rippe K, König R, Schroeder C. Höflmayer D, et al. Among authors: poos am. Mol Oncol. 2020 Jan;14(1):129-138. doi: 10.1002/1878-0261.12597. Epub 2019 Nov 29. Mol Oncol. 2020. PMID: 31736271 Free PMC article.
21 results